-
公开(公告)号:US5639781A
公开(公告)日:1997-06-17
申请号:US495814
申请日:1995-06-27
申请人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号: A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/40 , C07D209/08
CPC分类号: C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要: The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译: 本发明提供了含有下式化合物的组蛋白酶L抑制剂:其中R1是氢原子或可被取代的芳基烷基,杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基,磺酰基,羰基氧基,氨基甲酰基或硫代氨基甲酰基; X是式:-CHO或-CHOOB(其中B是氢原子或羟基保护基); m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基,被具有多于9个碳原子的芳基取代的磺酰基或低级烷基,或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基,甲基硫代乙基上的芳基烷基 ,R2和R3独立地是低级烷基或芳烷基,X是-CHO,m是1,n是0或1,或其盐。 化合物(I)可用作骨质疏松症的预防/治疗剂。
-
公开(公告)号:US5716980A
公开(公告)日:1998-02-10
申请号:US495097
申请日:1995-06-27
申请人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号: A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/40 , C07D209/20
CPC分类号: C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要: The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof. Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译: 本发明提供了含有下式化合物的组蛋白酶L抑制剂:其中R1是氢原子或可被取代的芳基烷基,杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基,磺酰基,羰基氧基,氨基甲酰基或硫代氨基甲酰基; X是式:-CHO或-CHOOB(其中B是氢原子或羟基保护基); m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基,被具有多于9个碳原子的芳基取代的磺酰基或低级烷基,或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基,甲基硫代乙基上的芳基烷基 ,R2和R3独立地是低级烷基或芳烷基,X是-CHO,m是1,n是0或1,或其盐。 化合物(I)可用作骨质疏松症的预防/治疗剂。
-
公开(公告)号:US5955491A
公开(公告)日:1999-09-21
申请号:US495352
申请日:1995-06-27
申请人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号: A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/405 , A61K31/195 , A61K31/41 , A61K31/435 , A61K31/495
CPC分类号: C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要: The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.
摘要翻译: 本发明提供了含有下式化合物的组织蛋白酶L抑制剂:其中R1是氢原子或可被取代的芳基烷基,杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基,磺酰基,羰基氧基,氨基甲酰基或硫代氨基甲酰基; X是式:-CHO或-CHOOB(其中B是氢原子或羟基保护基); m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基,被具有多于9个碳原子的芳基取代的磺酰基或低级烷基,或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基,甲基硫代乙基上的芳基烷基 ,R2和R3独立地是低级烷基或芳烷基,X是-CHO,m是1,n是0或1,或其盐。
-
公开(公告)号:US5498728A
公开(公告)日:1996-03-12
申请号:US192038
申请日:1994-02-04
申请人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
发明人: Takashi Sohda , Yukio Fujisawa , Tsuneo Yasuma , Junji Mizoguchi , Masakuni Kori , Masayuki Takizawa
IPC分类号: A61K38/55 , A61K31/16 , A61K31/165 , A61K31/18 , A61K31/27 , A61K38/00 , A61P3/00 , A61P3/02 , A61P43/00 , C07C231/12 , C07C233/18 , C07C233/22 , C07C233/31 , C07C237/10 , C07C237/22 , C07C271/16 , C07C271/18 , C07C271/22 , C07C303/40 , C07C311/19 , C07C337/02 , C07D209/14 , C07D209/16 , C07K1/113 , C07K5/06 , C07K5/062 , C07K14/81 , A61K31/40
CPC分类号: C07D209/16 , C07C233/18 , C07C233/22 , C07C233/31 , C07C271/16 , C07C271/18 , C07C271/22 , C07C311/19 , C07K5/06034 , A61K38/00 , Y02P20/55
摘要: The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.
摘要翻译: 本发明提供了含有下式化合物的组蛋白酶L抑制剂:其中R1是氢原子或可被取代的芳基烷基,杂环烷基或低级烷基; R2和R3独立地是氢原子或可以被取代的烃残基; R4是可以被取代的烷酰基,磺酰基,羰基氧基,氨基甲酰基或硫代氨基甲酰基; X是式:-CHO或-CHOOB(其中B是氢原子或羟基保护基); m和n独立地为0或1的整数; 条件是R4是被芳基取代的烷酰基,被具有多于9个碳原子的芳基取代的磺酰基或低级烷基,或当R 1是未取代的低级烷基时可被取代的氨基甲酰基或硫代氨基甲酰基,甲基硫代乙基上的芳基烷基 ,R2和R3独立地是低级烷基或芳烷基,X是-CHO,m是1,n是0或1,或其盐。 化合物(I)可用作骨质疏松症的预防/治疗剂。
-
公开(公告)号:US09527807B2
公开(公告)日:2016-12-27
申请号:US14009456
申请日:2012-04-05
申请人: Shoji Fukumoto , Osamu Ujikawa , Shinji Morimoto , Yasutomi Asano , Satoshi Mikami , Norihito Tokunaga , Masakuni Kori , Toshihiro Imaeda , Koichiro Fukuda , Shinji Nakamura , Kouichi Iwanaga
发明人: Shoji Fukumoto , Osamu Ujikawa , Shinji Morimoto , Yasutomi Asano , Satoshi Mikami , Norihito Tokunaga , Masakuni Kori , Toshihiro Imaeda , Koichiro Fukuda , Shinji Nakamura , Kouichi Iwanaga
IPC分类号: C07C311/07 , C07D401/12 , C07D309/14 , C07D295/092 , C07D333/16 , C07D231/12 , C07D211/58 , C07C311/09 , C07C311/14 , C07C317/28 , C07C323/26 , C07D209/04 , C07D213/64 , C07D231/14 , C07D233/68 , C07D261/08 , C07D263/32 , C07D277/24 , C07D277/62 , C07D307/22 , C07D405/12 , C07D413/12 , C07D417/12 , C07D405/14 , C07D309/06 , C07D213/85 , C07D401/04 , C07D237/04 , C07D239/28 , C07D409/12 , C07D493/08 , C07D207/27 , C07D207/273 , C07D277/32 , C07D211/56 , C07D211/76 , C07D295/192 , C07D213/61 , C07D305/06 , C07D233/56
CPC分类号: C07C311/07 , C07C311/09 , C07C311/14 , C07C317/28 , C07C323/26 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D207/27 , C07D207/273 , C07D209/04 , C07D211/56 , C07D211/58 , C07D211/76 , C07D213/61 , C07D213/64 , C07D213/85 , C07D231/12 , C07D231/14 , C07D233/56 , C07D233/68 , C07D237/04 , C07D239/28 , C07D261/08 , C07D263/32 , C07D277/24 , C07D277/32 , C07D277/62 , C07D295/092 , C07D295/192 , C07D305/06 , C07D307/22 , C07D309/06 , C07D309/14 , C07D333/16 , C07D401/04 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D493/08
摘要: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.
摘要翻译: 提供具有AMPA受体功能增强作用的化合物,可用作抑郁症,阿尔茨海默氏病,精神分裂症,注意力缺陷多动障碍(ADHD)等的预防或治疗药物。 由式(I)表示的化合物或其盐,其中每个符号如本说明书中所定义。
-
公开(公告)号:US07897607B2
公开(公告)日:2011-03-01
申请号:US10593891
申请日:2005-04-06
申请人: Albert Charles Gyorkos , Christopher Peter Corrette , Suk Young Cho , Timothy Mark Turner , Kazuyoshi Aso , Masakuni Kori , Michiyo Mochizuki , Kevin Ronald Condroski , Christopher Stephen Siedem , Steven Armen Boyd
发明人: Albert Charles Gyorkos , Christopher Peter Corrette , Suk Young Cho , Timothy Mark Turner , Kazuyoshi Aso , Masakuni Kori , Michiyo Mochizuki , Kevin Ronald Condroski , Christopher Stephen Siedem , Steven Armen Boyd
IPC分类号: C07D487/04 , A61K31/519
CPC分类号: C07D213/74 , C07C225/20 , C07C2602/08 , C07D215/233 , C07D215/56 , C07D231/56 , C07D237/28 , C07D239/46 , C07D239/47 , C07D239/56 , C07D239/94 , C07D239/95 , C07D239/96 , C07D265/36 , C07D455/02 , C07D471/04 , C07D487/04
摘要: There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W—Ar (I) wherein, A is a group represented by the formula (A1) or (A2): (wherein, ring Aa is a 5- or 6-membered ring which may be further substituted; ring Ab is a 5- or 6-membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R1 is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X is carbonyl, —O—, —S—, etc.; Y1, Y2 and Q are independently optionally substituted carbon or nitrogen; is a single or double bond); W is a bond, optionally substituted methylene, optionally substituted imino, —O—, —S—, etc.; Ar is optionally substituted aryl or optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.
摘要翻译: 提供了包含式(I)的化合物的CRF受体拮抗剂:AW-Ar(I)其中A是由式(A1)或(A2)表示的基团:(其中环Aa是5- 或6元环,其可以被进一步取代;环Ab是可进一步取代的5-或6-元环;环Ac是可被取代的5-或6-元环; R 1是任选取代的烷基, 取代的氨基,取代的羟基等; X是羰基,-O-,-S-等; Y1,Y2和Q独立地是任选取代的碳或氮;是单键或双键); W是一个键,任意取代的亚甲基,任选取代的亚氨基,-O - , - S-等; Ar是任选取代的芳基或任选取代的杂芳基; 或其盐或其前药。
-
公开(公告)号:US5698691A
公开(公告)日:1997-12-16
申请号:US311932
申请日:1994-09-26
IPC分类号: C12N9/99 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/554 , A61P3/06 , A61P43/00 , C07D223/16 , C07D243/04 , C07D243/10 , C07D243/12 , C07D243/14 , C07D243/16 , C07D243/24 , C07D245/06 , C07D255/04 , C07D257/04 , C07D267/14 , C07D267/22 , C07D281/10 , C07D285/00 , C07D417/06 , C07D417/12 , C07D498/04 , C07D267/02
CPC分类号: C07D223/16 , C07D243/04 , C07D243/12 , C07D243/24 , C07D255/04 , C07D267/14 , C07D281/10 , C07D417/06 , C07D417/12
摘要: Disclosed is a squalene synthetase inhibitor which comprises the compound represented by the formula ##STR1## wherein R.sub.1 is hydrogen or an optionally substituted hydrocarbon group; R.sub.2 is hydrogen, an optionally substituted alkyl group, an optionally substituted phenyl group or an optionally substituted aromatic heterocyclic ring group; X' is a substituent comprising an optionally esterified carboxyl group, an optionally substituted carbamoyl group, an optionally substituted hydroxyl group, an optionally substituted amino group or an optionally substituted heterocyclic radical having a protonizable hydrogen; Ring A is an optionally substituted benzene ring or an optionally substituted aromatic heterocyclic ring; Ring J' is a 7- to 8-membered heterocyclic ring containing at most three ring constituting hetero atoms; D is C or N; the Ring J' optionally having, besides R.sub.1, R.sub.2 and X', a further substituent; provided that the condensed ring composed of Ring A and ring J' is not a 2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine ring, or a pharmaceutically acceptable salt thereof, and which is useful for the prophylaxis or therapy of hypercholesteremia or coronary sclerosis of mammals.
摘要翻译: 公开了一种角鲨烯合成酶抑制剂,其包含由通式取代的烃基表示的化合物; R2是氢,任选取代的烷基,任选取代的苯基或任选取代的芳族杂环基; X'是包含任选酯化的羧基,任选取代的氨基甲酰基,任选取代的羟基,任选取代的氨基或具有可质子化氢的任选取代的杂环基的取代基; 环A是任选取代的苯环或任选取代的芳族杂环; 环J'是含有至多三个环构成杂原子的7-至8-元杂环; D为C或N; 除了R1,R2和X'之外,环J'还可以具有另外的取代基; 条件是由环A和环J'组成的稠环不是2-氧代-1,2,3,5-四氢-4,1-苯并氧氮杂环,或其药学上可接受的盐,并且其可用于 预防或治疗哺乳动物的高胆固醇血症或冠状动脉硬化。
-
公开(公告)号:US08575154B2
公开(公告)日:2013-11-05
申请号:US13206113
申请日:2011-08-09
申请人: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda , Yasutomi Asano , Osamu Ujikawa , Michiyo Mochizuki
发明人: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda , Yasutomi Asano , Osamu Ujikawa , Michiyo Mochizuki
IPC分类号: A61K31/549
CPC分类号: C07D513/04
摘要: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
摘要翻译: 提供式(I)表示的化合物:其中每个符号如说明书中所定义,或其盐,其具有AMPA(α-氨基-3-羟基-5-甲基-4-异恶唑丙酸)受体 增效作用 本发明的化合物可用作抑郁症,精神分裂症,阿尔茨海默病或注意缺陷多动障碍(ADHD)等的预防或治疗药物。
-
公开(公告)号:US07714009B2
公开(公告)日:2010-05-11
申请号:US10577334
申请日:2004-10-27
申请人: Albert Charles Gyorkos , Christopher Peter Corrette , Suk Young Cho , Timothy Mark Turner , Scott Alan Pratt , Kazuyoshi Aso , Masakuni Kori , Michiyo Gyoten
发明人: Albert Charles Gyorkos , Christopher Peter Corrette , Suk Young Cho , Timothy Mark Turner , Scott Alan Pratt , Kazuyoshi Aso , Masakuni Kori , Michiyo Gyoten
IPC分类号: A61K31/4168 , C07D403/12 , C07D403/14 , C07D235/30
CPC分类号: C07D235/30 , C07D471/04
摘要: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A′): wherein X is a carbon and X1 is an oxygen, a sulfur or —NR5—, or formula (A″): wherein X is a nitrogen and R6 is an optionally substituted hydrocarbyl, R1 is an amino substituted by two optionally substituted hydrocarbyl groups, R2 is an phenyl, Y1 is CR3a or a nitrogen, Y2 is CR3b or a nitrogen and Y3 is CR3c or a nitrogen, provided that one or less of Y1, Y2, and Y3 is nitrogen, W is a bond, —(CH2)n-, and Z is a bond, —NR4—, etc.; or a salt thereof or a prodrug thereof.
摘要翻译: 提供了包含式(I)化合物的CRF受体拮抗剂:其中环A是由式(A')表示的5元环:其中X是碳,X 1是氧,硫或 -NR5-或式(A“):其中X是氮,R6是任选取代的烃基,R 1是被两个任选取代的烃基取代的氨基,R 2是苯基,Y 1是CR 3 a或氮,Y 2是 CR3b或氮,Y3为CR3c或氮,条件是Y1,Y2和Y3中的一个或多个为氮,W为键, - (CH2)n-,Z为键,-NR4-等 。 或其盐或其前药。
-
公开(公告)号:US20080058310A1
公开(公告)日:2008-03-06
申请号:US11810887
申请日:2007-06-07
IPC分类号: A61K31/553 , A61P3/00
CPC分类号: C07D267/14 , A61K31/553
摘要: A novel high-density lipoprotein(HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.
摘要翻译: 一种含有具有角鲨烯合酶抑制活性的化合物的新型高密度脂蛋白(HDL) - 胆固醇水平升高剂。
-
-
-
-
-
-
-
-
-